Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT05417737
Active, not recruiting Observational

Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025

NCT05417737 · tracked via the Priya Life Science Spain tracker
Sponsor
Bernardino Clavo, MD, PhD
Phase
Observational
Started
2022-06-15
Last updated
2026-09-25

Condition(s) studied

Radiation ToxicityChemotherapeutic ToxicityChemotherapy-induced Peripheral NeuropathyDelayed Wound HealingChronic PainRefractory Pain

Investigational drug(s) / intervention(s)

Ozone therapy

Ozone therapy: Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.

Study summary

The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adults \> = 18 years old. 2. Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín for symptomatic/palliative treatment with ozone therapy because conventional treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity. 3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment. 4. Patients have no contraindications for ozone treatment. 5. Patients have signed and dated the informed consent for the compassionated ozone treatment and the specific informed consent for this study Exclusion Criteria: 1. Age \< 18 years old. 2. Psychiatric illness or social situations that would limit compliance with study requirements. 3. Those who are incapable to fill in the scales used to measure variables. 4. Hemodynamically or clinically unstable patients or uncontrolled severe illness. 5. Uncontrolled cancer disease requiring chemotherapy treatment. 6. Life expectancy \< 6 months 7. Contraindication or disability or to attend scheduled treatments. 8. Known allergy to ozone. 9. Pregnancy at the time of enrollment (for systemic ozone therapy). 10 Hemochromatosis (for systemic ozone therapy). 11\. Known significant glucose-6-phosphate dehydrogenase deficiency (favism, acute hemolytic anemia) (for systemic ozone therapy). 12\. Patients who do not meet all the inclusion criteria

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dr. Negrín University Hospital Las Palmas Las Palmas

More Bernardino Clavo, MD, PhD trials in Spain

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05417737 on ClinicalTrials.gov ↗ ← All trials in Spain